Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%
HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$2.22B
EPS-1.0400
P/E Ratio-20.70
Earnings Date05/13/2026

dawn

Net Cash Provided by Financing Activities

Last Annual Value

1.22M

3-Year CAGR

-81%

5-Year CAGR

-47%

10-Year CAGR

-28%

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

DAWN · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.22M
-80.5%-66.7%N/A 
2.27M
-81.6%-45.8%6.8%
157.20M
21.2%8.6%32.9%
8.10M
74.0%-51.8%N/A
203.06M
68.0%17.7%N/A
ARVN logo
Arvinas, Inc.
NASDAQ:ARVN
-91.40M
N/AN/AN/A
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
1.10M
-5.4%-69.8%N/A
3.79M
-20.0%-48.1%N/A
252.40M
-6.8%-7.5%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
107.33M
110.1%15.8%25.9%
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Fair Value Envelope

DAWN · NASDAQ

Our analysis suggests that DAWN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.53, this represents a potential HIDDEN relative to our calculated worth for Day One Biopharmaceuticals, Inc..

Intrinsic Value
Current Price: $21.53